Guidance and quality standards In consultation
Showing 1 to 1 of 1
Title | Consultation | Type | Consultation end date |
---|---|---|---|
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132] | Draft guidance | Technology appraisal guidance |